The Association of Glomerular Filtration Rate With Echocardiographic Parameters in Chronic Kidney Disease.
Aortic propagation velocity
Carotid intima-media thickness
Chronic kidney disease
Epicardial fat thickness
Journal
Journal of clinical medicine research
ISSN: 1918-3003
Titre abrégé: J Clin Med Res
Pays: Canada
ID NLM: 101538301
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
03
02
2021
accepted:
16
02
2021
entrez:
22
3
2021
pubmed:
23
3
2021
medline:
23
3
2021
Statut:
ppublish
Résumé
Cardiovascular disease (CVD) is the primary cause of mortality and morbidity in chronic kidney disease (CKD) patients. Aortic propagation velocity (APV), epicardial fat thickness (EFT) and carotid intima-media thickness (CIMT) measurements could provide additional information on assessing renal decline in CKD patients. The study aimed to evaluate EFT, AVP and CIMT in CKD patients and then investigate the association among those parameters. A total of 170 CKD consecutive subjects were enrolled in the study. Patients were divided into five groups according to their estimated glomerular filtration rate (eGFR) values. Each patient underwent complete transthoracic echocardiography examination. APV, EFT and CIMT were measured for analyses. A multivariate linear regression model was used for analysis to determine the independent predictors of eGFR. The lowest APV was observed in stage IV-V, and the highest APV was observed in stage I-II (P < 0.001). Stage IV-V patients had the highest EFT and stage I-II patients had the lowest EFT (P < 0.001). Moreover, the lowest CIMT was observed in stage III, and the highest CIMT was observed in stage V (P < 0.001). eGFR was significantly and positively correlated with APV and negatively correlated with EFT and CIMT. In multivariate analyses, APV (odds ratio (OR): 0.289, P < 0.001), EFT (OR: -0.135, P < 0.001) and CIMT (OR: -0.388, P < 0.001) were independent predictors of eGFR. We found that APV decreased, and EFT and CIMT increased as CKD progress. The present study suggests that APV, EFT and CIMT might be incorporated with the examination of CKD patients in daily practice.
Sections du résumé
BACKGROUND
BACKGROUND
Cardiovascular disease (CVD) is the primary cause of mortality and morbidity in chronic kidney disease (CKD) patients. Aortic propagation velocity (APV), epicardial fat thickness (EFT) and carotid intima-media thickness (CIMT) measurements could provide additional information on assessing renal decline in CKD patients. The study aimed to evaluate EFT, AVP and CIMT in CKD patients and then investigate the association among those parameters.
METHODS
METHODS
A total of 170 CKD consecutive subjects were enrolled in the study. Patients were divided into five groups according to their estimated glomerular filtration rate (eGFR) values. Each patient underwent complete transthoracic echocardiography examination. APV, EFT and CIMT were measured for analyses. A multivariate linear regression model was used for analysis to determine the independent predictors of eGFR.
RESULTS
RESULTS
The lowest APV was observed in stage IV-V, and the highest APV was observed in stage I-II (P < 0.001). Stage IV-V patients had the highest EFT and stage I-II patients had the lowest EFT (P < 0.001). Moreover, the lowest CIMT was observed in stage III, and the highest CIMT was observed in stage V (P < 0.001). eGFR was significantly and positively correlated with APV and negatively correlated with EFT and CIMT. In multivariate analyses, APV (odds ratio (OR): 0.289, P < 0.001), EFT (OR: -0.135, P < 0.001) and CIMT (OR: -0.388, P < 0.001) were independent predictors of eGFR.
CONCLUSION
CONCLUSIONS
We found that APV decreased, and EFT and CIMT increased as CKD progress. The present study suggests that APV, EFT and CIMT might be incorporated with the examination of CKD patients in daily practice.
Identifiants
pubmed: 33747327
doi: 10.14740/jocmr4439
pmc: PMC7935629
doi:
Types de publication
Journal Article
Langues
eng
Pagination
121-129Informations de copyright
Copyright 2021, Ozdemir et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.
Références
Kidney Int. 2012 Aug;82(4):388-400
pubmed: 22534962
JAMA. 2005 Apr 13;293(14):1737-45
pubmed: 15827312
Int J Clin Exp Med. 2014 Jul 15;7(7):1794-801
pubmed: 25126182
J Am Soc Nephrol. 2016 Jun;27(6):1837-46
pubmed: 26475595
J Intern Med. 2015 Jul;278(1):77-87
pubmed: 25556720
Ren Fail. 2019 Nov;41(1):131-138
pubmed: 30909780
Ren Fail. 2013 Jul;35(6):891-5
pubmed: 23713741
Acta Cardiol Sin. 2017 May;33(3):266-272
pubmed: 28559657
Atherosclerosis. 2013 Jan;226(1):129-33
pubmed: 23159099
Hypertension. 2001 May;37(5):1236-41
pubmed: 11358934
J Family Med Prim Care. 2019 Apr;8(4):1447-1452
pubmed: 31143737
Am J Nephrol. 2017;45(1):72-81
pubmed: 27898419
Int Urol Nephrol. 2020 Dec;52(12):2345-2355
pubmed: 32720030
Kidney Int. 2006 Jan;69(2):350-7
pubmed: 16408126
Heart Fail Rev. 2017 Nov;22(6):889-902
pubmed: 28762019
Acta Cardiol Sin. 2017 Jan;33(1):74-80
pubmed: 28115810
J Am Soc Nephrol. 2001 Nov;12(11):2458-64
pubmed: 11675423
Bratisl Lek Listy. 2018;119(9):566-571
pubmed: 30226067
Med Sci Monit. 2008 Sep;14(9):MT42-6
pubmed: 18758427
Rev Diabet Stud. 2011 Fall;8(3):403-17
pubmed: 22262077
Heart. 2013 Mar;99(6):365-72
pubmed: 23118349
N Engl J Med. 1999 Jan 7;340(1):14-22
pubmed: 9878640
Diabetes Metab Syndr Obes. 2019 Sep 19;12:1889-1896
pubmed: 31571963
J Hum Hypertens. 2020 Sep;34(8):577-585
pubmed: 31664172
Atherosclerosis. 2015 Aug;241(2):507-32
pubmed: 26117398
J Cardiol. 2013 Oct;62(4):236-40
pubmed: 23778004
Circ J. 2016;80(1):196-201
pubmed: 26497330
Zhonghua Xin Xue Guan Bing Za Zhi. 2017 Feb 24;45(2):121-125
pubmed: 28260317
Circulation. 2001 Feb 20;103(7):987-92
pubmed: 11181474
Heart. 2008 Aug;94(8):1038-43
pubmed: 18308865
Adv Chronic Kidney Dis. 2008 Oct;15(4):396-412
pubmed: 18805386
Arch Med Sci. 2017 Jun;13(4):864-874
pubmed: 28721155
J Am Soc Nephrol. 2006 Oct;17(10):2937-44
pubmed: 16988059